Biological Characteristics and Long-term Outcomes in Node-negative Breast Cancer
Elisa Agostinetto(Université Libre de Bruxelles), Armando Santoro(IRCCS Humanitas Research Hospital), Giovanna Masci(Humanitas University), Marco Alloisio(IRCCS Humanitas Research Hospital), Monica Zuradelli(Humanitas University), Rita De Sanctis(Humanitas University), Wolfgang Gatzemeier(IRCCS Humanitas Research Hospital), Rosalba Torrisi(IRCCS Humanitas Research Hospital), Laura Giordano(Istituti di Ricovero e Cura a Carattere Scientifico), Agnese Losurdo(Humanitas University), Alberto Testori(IRCCS Humanitas Research Hospital), Corrado Tinterri(Humanitas University), Bethania Fernandes(Humanitas University), Fiorenza De Rose
Cited by 4
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532